帕米磷酸二钠治疗恶性肿瘤骨转移高钙血症的价值

The value of Pamidronate Disodium in the treatment of hypercalcemia of bone metastases from malignant tumors

目的探讨帕米磷酸二钠治疗恶性肿瘤骨转移高钙血症的价值。方法 100例恶性肿瘤骨转移高钙血症的患者,随机分为研究组与对照组,各50例。研究组接受帕米磷酸二钠治疗,对照组接受唑来磷酸治疗。观察比较两组治疗前后血钙水平及血磷水平;两组恶性肿瘤骨转移的治疗疗效。结果治疗前,两组血钙水平及血磷水平比较差异无统计学意义(P>0.05)。治疗后,研究组血钙水平及血磷水平均优于对照组,差异具有统计学意义(P<0.05)。研究组治疗总有效率96%(48/50)高于对照组的80%(40/50),差异具有统计学意义(P<0.05)。结论帕米磷酸二钠可以减少恶性肿瘤骨转移患者高钙血症,提高治疗疗效,减轻骨转移造成的疼痛。

Objective To explore the value of Pamidronate Disodium in the treatment of hypercalcemia of bone metastases from malignant tumors. Methods A total of 100 patients with hypercalcemia of bone metastases from malignant tumors were randomly divided into research group and control group, 50 cases in each group. The research group received Pamidronate Disodium for treatment, the control group received Zoledronic Acid for treatment. The levels of serum calcium and serum phosphorus before and after treatment, the therapeutic effect of bone metastases from malignant tumors were compared between the two groups. Results Before treatment, there were no statistically significant differences in the levels of serum calcium and serum phosphorus between the two groups（P〈0.05）. The levels of serum calcium and serum phosphorus in the research group after treatment were significantly better than those in the control group, the differences were statistically significant（P〈0.05）. The total effective rate of treatment in the research group was 96%（48/50）, which was significantly higher than 80%（40/50） in the control group, the difference was statistically significant（P〈0.05）. Conclusion Pamidronate Disodium can reduce the incidence of hypercalcemia in patients with bone metastases from malignant tumors, improve therapeutic efficacy and relieve pain caused by bone metastases.